|
| Exchange Disseminated Time | With reference to Development relating to withdrawal by Ranbaxy of 27 approved ANDAs in the USA market appearing on US Regulator website and on certain online portals, Ranbaxy Laboratories Ltd has Clarified to BSE that the Company has determined that certain products with negligible commercial impact should be withdrawn to enable the organization to focus resources on other applications that are of greater importance and value to the US business and healthcare system.
Further, the aforesaid ANDAs do not pertain to current business and will have a negligible impact on the Company’s business in USA. |
|
|